about us
|
technology
|
product development
|
partnering
|
corporate communications
|
career
|
contact
|
Pieris is a biopharmaceutical company engaged in the discovery and
development of Anticalins®, a novel class of targeted protein
therapeutics, for the diagnosis and treatment of
severe human disorders.
recent news
--- Pieris raises € 25 M (US$ 38 M) in Series B financing round led by OrbiMed Advisors LLC ---
©
Pieris AG 2008
|
sitemap
|
disclaimer
|
contact
|
|